EC to terminate Covid-19 vaccine deal with Valneva

The European Commission (EC) has informed Valneva of its plan to terminate the advance purchase agreement (APA) for the latter’s inactivated whole-virus Covid-19 vaccine candidate, VLA2001. The details were communicated by the EC through a notice to the company. An adjuvanted vaccine candidate, VLA2001 is for active immunisation of at-risk people to avert carriage and symptomatic Covid-19 infection. It comprises inactivated whole virus particles of the SARS-CoV-2 virus with increased S-protein density and two adjuvants, alum and Dynavax Technologies’ CpG 1018.